Alemtuzumab Maintains Long-Term Efficacy in MS, Shows Superiority to Interferon Beta
May 30th 2019Follow-up data extending out to 8 years suggest that both clinical and MRI outcomes are better with alemtuzumab (Lemtrada) than interferon beta-1a in patients with relapsing-remitting multiple sclerosis.
Higher-Efficacy DMTs May Have Favorable Effect on Depression in MS
May 29th 2019Given that depression is a common symptom in patients with MS and is associated with increased morbidity and mortality, the investigators examined the effects of lower-efficacy DMTs and higher-efficacy DMTs on depression.
Nonadherence to Disease-Modifying Treatment in MS Has Significant Clinical and Economic Effects
May 29th 2019In order to better understand the clinical and economic impacts of nonadherence to disease-modifying therapy, the investigators conducted a cost-consequence analysis among patients taking once- or twice-daily DMTs.
Cladribine Reduces MRI Lesions Across Subgroups in ORACLE-MS Study
May 28th 2019The subgroups were defined by baseline characteristics that are known to be potential modifiers of risk to conversion to clinically-definite multiple sclerosis, including age, gender, first classification of demyelinating event, presence of T1 Gd+ lesions, and number of active T2 lesions.
Advocacy Groups Look Toward Increasing Support for Providers in Rare Neurological Disorders
May 25th 2019The National Organization for Rare Disorders is home base for more than 300 member organizations that serve not just patients, but providers who care for those with rare disorders, such as SMA and Duchenne muscular dystrophy.